Skip to content
Clinical Trials – home

Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy

VerifiedinfoResponsive

Poland Alpejska 42, 04-628 Warsaw, Poland

  • 22 trials recruiting
  • Arteriosclerosis · Atrial fibrillation · Cardiac failure
  • Adult patients

About Specializations

Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy in Warsaw, Poland specialises in clinical trials of conditions such as Arteriosclerosis, Atrial fibrillation, Cardiac failure, Hypertension, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Diseases

At the Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego, the epidemiology department advances research on cardiovascular diseases by evaluating new therapeutic approaches and assessing their impact on clinical outcomes.

  • Heart failure with preserved or reduced ejection fraction
  • Hypertrophic cardiomyopathy and atrial fibrillation
  • Coronary artery disease and atherosclerotic risk
  • Hypertension, including resistant forms
  • Arrhythmogenic and dilated cardiomyopathies
  • Acute myocardial infarction and post‑event risk reduction

The initiative leverages extensive patient registries to uncover risk patterns and fosters multicenter collaborations throughout Europe.

Nutritional and Metabolic Diseases

Research at the institute focuses on nutritional and metabolic diseases, seeking to improve prevention strategies and evaluate therapies that address obesity, diabetes, and related metabolic disorders.

  • Obesity and overweight in individuals with cardiovascular risk
  • Prediabetes management in patients with coronary artery disease
  • Type 2 diabetes treatment with emerging agents
  • Hyperlipidemia and lipoprotein(a) lowering interventions
  • Uric acid metabolism and its cardiovascular implications

By integrating metabolic profiling, the program aims to identify early biomarkers and support lifestyle‑focused interventions alongside pharmacologic options.

Respiratory Tract Diseases

The epidemiology unit also investigates respiratory tract diseases, emphasizing the interplay between breathing disorders and heart health while testing novel diagnostic and therapeutic measures.

  • Obstructive sleep apnea in overweight adults
  • Pulmonary hypertension secondary to heart failure with preserved ejection fraction
  • Impact of chronic respiratory conditions on cardiovascular outcomes

Collaborative efforts with pulmonology specialists enable comprehensive assessments and the development of integrated care pathways for affected patients.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Alpejska 4204-628 WarsawPoland
Recruiting now
22 trials
Conditions studied
39
Partner status
Verified

More sites in WarsawPoland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

54 clinical trials

Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:Novo Nordisk A/S
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:ZILEBESIRAN
  • Sponsor:Alnylam Pharmaceuticals Inc.
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:AstraZeneca AB
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Selatogrel
  • Sponsor:Viatris Innovation GmbH
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Azd5004
  • Sponsor:AstraZeneca AB
Countries:PolandPoland
  • Participants:65+ years
  • Substances:Sodium Chloride
  • Sponsor:Wroclaw Medical University
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Danicamtiv
  • Sponsor:Kardigan Inc.
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:Alnylam Pharmaceuticals Inc.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.